Form 990 for tax year 2023

Totals

Total revenue

$31,646,627

Total expenses

$34,355,201

Contributions and grants received

$23,286,921

Grants paid

$0

Program service revenue

$7,728,039

Investment income

$602,254

Other revenue

$29,413

Total assets, end of year

$17,246,189

Total liabilities, end of year

$12,030,150

Net assets or fund balances, end of year

$5,216,039

Program services expenses (Part IX)

$29,271,270

Management and general expenses

$5,083,931

Fundraising expenses

$0

Program service expenses (Part III)

$29,271,270

Program services were 85.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2023

• All of Us Research Program. Principal investigators: Philip Tsao, Ph.D.The All of Us Research Program (All of Us) is a large collaborative initiative sponsored by the National Institutes of Health (NIH). All of Us includes a consortium of awardees from multiple institutions, including the Department of Veterans Affairs. All of Us is working to improve healthcare through research by building a diverse database of participant self-report information, biospecimens, and Electronic Health Records that can inform future research on a variety of health conditions.continued in Schedule OVA participation in All of Us is overseen by three Co-PIs, located at the VA Palo Alto Health Care System and the VA Boston Healthcare System. These two institutions serve as the Coordinating Centers for VA responsible for centralized recruitment, engagement campaigns, and compliance with program requirements.

  Expenses $1,885,114 · Revenue $1,885,114

• Cell Atlas of Human Intestinal Lumphoid Tissues and Changes in Crohn's Disease: Eugene Butcher, M.D. The Helmsley funded project is part of a multi-year research study designed to generate a comprehensive atlas of the gastrointentinal (GI) tract at single cell resolution. Our focus is on the lymphoid tissues and immune cells of the gut wall in healthy and Crohn's disease patients, and in cooperation with our colleagues from Lund University of Sweden, we have produced transcriptomal profiles of over a million cells representing both immune (esp CD4 lymphocytes) and stromal cell populations.continued in Schedule OThese data are being incorporated into public datasets with interactive interfaces to allow scientists throughout the world to mine them for insights into the healthy and diseased intestinal immune system. This year we continued integration efforts towards this end. In addition, we used our generated data with others for key insights into the complexity, tissue imprinting, and lineage-specific precursors within the mononuclear phagocyte compartment of the human intestines. And the project data generated at the VA Palo Alto supported our discovery of a novel lymphocyte trafficking program, the CXCL17-GPR25 axis that directs lymphocytes and controls immune responses and tolerance in non-intestinal mucosa including the airways, nose, eye, stomach, oral cavity, vagina and GU tract and biliary tract (Nature, 2024). The study has yielded over 25 peer reviewed manuscripts, with this seminal Nature study published in the last year. Additionally, presentations at both national and international meetings have been made to share the progress of this study.

  Expenses $1,376,923 · Revenue $611,799

• Clinical Translation of Allogeneic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia: Irene Lorenzo Llorente, Ph.D.Stroke is the leading cause of adult disability and the second leading cause of dementia. White matter stroke (WMS) constitutes up to 30% of all stroke subtypes and it is a distinct process from "large artery stroke". continued in Schedule OWMS starts as small infarcts in deep penetrating blood vessels in the brain but progresses, accumulates, and expands from preexisting lesions into adjacent white matter to produce hemiparesis with incomplete recovery, gait abnormalities, cognitive decline, and difficulties in executive functioning that present as vascular dementia. Unlike "large artery stroke", WMS does not damage neuronal cell bodies but damages axonal tracts and glial cells. Therefore, a cell-based therapy that can replace lost glia and induce structural repair in WMS/VaD is of great promise. We have developed a unique allogenic human induced pluripotent stem cell (hiPSC) derived Glial Enriched Progenitor (GEP) cell therapy product for the treatment of WMS and VaD. We have demonstrated that hiPSC-GEPs transplanted into the brain after WMS/VaD promoted motor and cognitive recovery through 3 mechanisms of action: axonal growth, astrocytic modulation, oligodendrocyte differentiation, and remyelination. To date, we have also qualified the entire manufacturing process for the intended therapeutic candidate, hiPSC-GEPs, through safety, identity, purity, activity, and stability qualification assays. To demonstrate the scale-up manufacturing capabilities of the potential therapeutic product, we have developed a new cGMP manufacturing protocol and produced well above the necessary number of cells for phases 1 and 2 of a future clinical application. This preliminary work could pave the way for a faster route to pre-IND, FDA approval, and a future clinical application.

  Expenses $1,192,502 · Revenue $1,192,502

• PAVIR is privileged to work with a large community of uniquely talented medical researchers across a broad spectrum of research areas as we fulfill our mission of advancing Veterans and public health through innovative research. The range of research activities is broad and includes special emphasis on major disease categories, all of which are prevalent in the VA's patient population. These include cardiovascular medicine, mental health, chronic inflammatory disease, stem cell/regenerative medicine, pain, sleep disorders, and many others. In addition to disease specific research, PAVIR is engaged in supporting research aimed at enhancing health care. PAVIR's research portfolio includes comparative studies in which research teams are learning which treatments are superior to others, how to augment or improve standard of care, as well as how to enhance the operation of health care. Furthermore, PAVIR is supporting educational activities, especially in areas of advancing clinical care for Veterans and fostering the professional development of our expert staff.

  Expenses $24,816,731 · Revenue $7,728,039

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• VA Palo Alto Health Care System

  501(c)(1) · Teaching hospital, providing a full range of patient care services · CA

Provenance

Return type

form_990

Tax year

2023

Filed

1 May 2025

IRS schema version

2023v6.0

Source object

202501269349302435

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.